iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Dr Reddy's, Glenmark, and Zydus Recall Products in the US Over Manufacturing Issues

22 Nov 2023 , 03:48 PM

Dr Reddy's Laboratories, Glenmark Pharma, and Zydus are recalling products in the US market due to manufacturing issues, as per the US Food and Drug Administration (USFDA). 

  • Dr Reddy's Laboratories, Inc., a unit of the Hyderabad-based firm, is recalling 1,656 bottles of Montelukast sodium tablets used to prevent asthma symptoms. The recall is attributed to the 'presence of foreign tablets and capsules,' with a foreign tablet identified as metoprolol 25 mg found in a bottle of Montelukast sodium tablets, USP 10mg.
  • Glenmark Pharmaceuticals Inc, USA, a unit of Mumbai-based Glenmark Pharma, is recalling 5,856 bottles of Deferasirox tablets for oral suspension, used to treat iron overload. The recall is due to 'failed dissolution specifications.' Glenmark Pharmaceuticals Inc is also recalling 16,944 bottles of Ranolazine Extended-Release tablets, used for chronic chest pain, in the US due to 'failed dissolution specifications.'
  • Zydus Pharmaceuticals (USA) Inc is recalling Oxybutynin Chloride extended-release tablets in different strengths due to 'failed dissolution specifications-out-of-specification test results.' The affected lot was manufactured by Cadila Healthcare Ltd, Baddi, Himachal Pradesh.

The recalls are classified as Class II, where the use or exposure to the violative product may cause temporary or medically reversible adverse health consequences, with a remote probability of serious adverse health consequences, according to the USFDA.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Dr Reddys
  • Glenmark
  • news
  • Zydus
sidebar mobile


12 Apr 2024   |   01:37 PM
12 Apr 2024   |   10:20 AM
12 Apr 2024   |   10:16 AM
Read More

Most Read News

12 Apr 2024   |   08:25 PM
12 Apr 2024   |   08:14 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:13 PM
12 Apr 2024   |   08:08 PM
Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.


Get better recommendations & make better investments

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp